Download Oncogene inhibitors market & pipeline insight 2015

Download Oncogene inhibitors market & pipeline insight 2015

• 1.
  Oncogene Inhibitors Market& Pipeline Insight 2015 For Sample Contact: [email protected] , +91-11-47067990 Page 1 Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and identification of genetic factors are expected to shed more light on their working. It will allow the investigators to develop drugs capable of preventing oncogene activation and activity in the body. Development of such therapeutics is a daunting task because human genome is quite big and consists of variety of genes whose function has yet to be determined by investigators. Oncogene Inhibitor market is a rapidly growing segment with numerous products at different stages of clinical pipeline and marketed products at different phases of industry life cycle. Pharmaceutical companies are trying to provide efficient medical care to patients and generate significant revenues by their sales. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Several competitors are available for wide range of malignancies which further makes it imperative for them to provide both therapeutic and financial benefit to the patients. Due to which large numbers of pharmaceutical companies are expected to improve their products to achieve higher sales. Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criteria's set by regulatory authorities. Researchers are trying to develop new formulations to have better safety and efficacy profiles along with minimized side effects. Number of oncogene inhibitor for treatment of different malignancies is increasing every year due to which their market shares are expected to increase several folds in coming years. Escalating competition could be considered as one of the biggest driver for oncogene inhibitor therapeutics because this segment has significantly large number of products. Different oncogene inhibitors have been successfully commercialized by different pharmaceutical companies in past few decades. Oncogenes like c-met and c-myc are one of the most commonly used targets for inhibitors due their involvement in various cancers.
• 2.
  Oncogene Inhibitors Market& Pipeline Insight 2015 For Sample Contact: [email protected] , +91-11-47067990 Page 2 This biological phenomenon has given rise to therapeutics which could be commercialized for different cancer categories. In this way, more revenues could be generated and competition could be offered to other cancer therapeutics due to superior therapeutic efficacy. Ras gene was one of the earliest oncogene identified by investigators known to have proto-oncogenic in nature. However, therapeutic for this gene not available in market due to its complex protein structure that is impregnable by oncogenic inhibitors. “Oncogene Inhibitors Market & Pipeline Insight 2015" Report Highlight: • Global Oncogene Inhibitors Market Overview • Oncogene Inhibitors Pipeline by Company, Indication & Phase • Oncogene Inhibitors Pipeline: 185 Drugs • Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs • Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs • Proto Oncogene Protein c-akt Inhibitors: 39 Drugs • Marketed Oncogene Inhibitors: 22 Drugs • Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs For Report Sample Contact: [email protected]
• 3.
  Oncogene Inhibitors Market& Pipeline Insight 2015 For Sample Contact: [email protected] , +91-11-47067990 Page 3 Table of Contents 1. Introduction to Oncogene Inhibitors 2. Mechanism of Oncogene Inhibitors 3. Global Oncogene Inhibitors Market Overview 3.1 Current Market Scenario 3.2 Oncogene Inhibitors Clinical Pipeline Insight 4. Global Oncogene Inhibitor Market Dynamics 4.1 Favorable Market Parameters 4.2 Commercialization Challenges 5. Global Oncogene Inhibitor Market Future Prospects 6. Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase 6.1 Preclinical 6.2 Suspended & Discontinued 7. Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Company, Indication & Phase 7.1 Research till Preregistration 7.2 Marketed Drug Clinical Insight 7.3 Suspended & Discontinued 8. Proto Oncogene Protein b raf Inhibitors Pipeline by Company, Indication & Phase 8.1 Research till Phase-III 8.2 Marketed Drug Clinical Insight 8.3 Suspended & Discontinued
• 4.
  Oncogene Inhibitors Market& Pipeline Insight 2015 For Sample Contact: [email protected] , +91-11-47067990 Page 4 9. Proto Oncogene Protein c-kit Inhibitors Pipeline by Company, Indication & Phase 9.1 Research till Preregistration 9.2 Marketed Drug Clinical Insight 9.3 Suspended & Discontinued 10. Proto-Oncogene Protein c-rel Inhibitors Pipeline by Company, Indication & Phase 10.1 Research 11. Proto Oncogene Protein c-akt Inhibitors Pipeline by Company, Indication & Phase 11.1 Preclinical till Phase-III 11.2 Suspended & Discontinued 12. Proto Oncogene Protein c met Inhibitors Pipeline by Company, Indication & Phase 12.1 Preclinical till Phase-III 12.2 Marketed Drug Clinical Insight 12.3 Suspended & Discontinued 13. Proto Oncogene Protein c ret Inhibitors Pipeline by Company, Indication & Phase 13.1 Preclinical till Phase-III 13.2 Marketed Drug Clinical Insight 13.3 Suspended & Discontinued 14. Proto-Oncogene Protein c mdm2 Inhibitors Pipeline by Company, Indication & Phase 14.1 Preclinical till Phase-I/II 14.2 Suspended & Discontinued 15. Proto-Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase 15.1 Preclinical
• 5.
  Oncogene Inhibitors Market& Pipeline Insight 2015 For Sample Contact: [email protected] , +91-11-47067990 Page 5 16. Proto-Oncogene-Protein-c-ets Inhibitors Pipeline by Company, Indication & Phase 16.1 Preclinical 17. Proto-Oncogene Protein c-fli-1 Inhibitors Pipeline by Company, Indication & Phase 17.1 Preclinical 18. Proto Oncogene Proteins c pim 1 Inhibitors Pipeline by Company, Indication & Phase 18.1 Preclinical till Phase-I/II 18.2 Suspended & Discontinued 19. Proto Oncogene Protein c-myc Inhibitors Pipeline by Company, Indication & Phase 19.1 Preclinical till Phase-I/II 19.2 Marketed Drug Clinical Insight 20. Proto Oncogene Proteins c raf Inhibitors Pipeline by Company, Indication & Phase 20.1 Suspended & Discontinued 21. Proto Oncogene Proteins c myb Inhibitors Pipeline by Company, Indication & Phase 22. Multiple Oncogene Inhibitors Pipeline by Company, Indication & Phase 22.1 Preclinical till Registered 22.2 Marketed Drug Clinical Insight 22.3 Suspended & Discontinued 23. Competitive Landscape 23.1 AstraZeneca 23.2 ArQule Inc 23.3 Biogen Idec 23.4 Boehringer Ingelheim 23.5 Celgene Corporation
• 6.
  Oncogene Inhibitors Market& Pipeline Insight 2015 For Sample Contact: [email protected] , +91-11-47067990 Page 6 23.6 Constellation Pharmaceutical 23.7 Epizyme Pharmaceutical 23.8 Genentech 23.9 GalaxoSmithKline 23.10 Incyte Corporation 23.11 Johnson & Johnson 23.12 Merck 23.13 Novartis 23.14 Onyx pharmaceuticals 23.15 Pfizer List of Figures Figure 1-1: Features of Oncogenes Figure 1-2: Types of Genes Figure 1-3: Factors Responsible for Conversion of Proto-Oncogenes to Oncogenes Figure 2-1: Activation of Proto-Oncogenes to Oncogenes Figure 2-2: Benefits of Oncogene Inhibitors Figure 2-3: Mechanism of Crizotinib Figure 2-4: Mechanism of Vemurafenib Figure 2-5: Mechanism of Vorinostat Figure 3-1: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase (%), 2015 Figure 3-2: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase (Number), 2015
• 7.
  Oncogene Inhibitors Market& Pipeline Insight 2015 For Sample Contact: [email protected] , +91-11-47067990 Page 7 Figure 3-3: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase (%), 2015 Figure 3-4: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase (Number), 2015 Figure 3-5: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase (%), 2015 Figure 3-6: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase (Number), 2015 Figure 3-7: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase (%), 2015 Figure 3-8: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase (Number), 2015 Figure 3-9: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase (%), 2015 Figure 3-10: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase (Number), 2015 Figure 3-11: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase (%), 2015 Figure 3-12: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase (Number), 2015 Figure 3-13: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase (%), 2015 Figure 3-14: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase (Number), 2015 Figure 3-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase (%), 2015 Figure 3-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase (Number), 2015 Figure 3-17: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase (%), 2015 Figure 3-18: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase (Number), 2015 Figure 3-19: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase (%), 2015 Figure 3-20: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase (Number), 2015 Figure 3-21: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase (%), 2015 Figure 3-22: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase (Number), 2015 Figure 3-23: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase (%), 2015
• 8.
  Oncogene Inhibitors Market& Pipeline Insight 2015 For Sample Contact: [email protected] , +91-11-47067990 Page 8 Figure 3-24: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase (Number), 2015 Figure 3-25: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase (%), 2015 Figure 3-26: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase (Number), 2015 Figure 3-27: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase (%), 2015 Figure 3-28: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase (Number), 2015 Figure 3-29: Multiple Oncogene Inhibitors Pipeline by Phase (%), 2015 Figure 3-30: Multiple Oncogene Inhibitors Pipeline by Phase (number), 2015 Figure 3-31: Discontinued Multiple Oncogene Inhibitors Pipeline by Phase (%), 2015 Figure 3-32: Discontinued Multiple Oncogene Inhibitors Pipeline by Phase (Number), 2015 Figure 4-1: Oncogene Inhibitor Market Favorable Parameters Figure 4-2: Commercialization Challenges to Oncogene Inhibitors For Report Sample Contact: [email protected]